Extracellular matrix components at sites of vascular injury

The extracellular matrix (ECM) components at sites of vascular injury represent a complex assembly of structural proteins, including collagen (Types I, III, and IV), von Willebrand factor (vWF), fibronectin, and laminin, which become exposed to circulating blood when the protective endothelial layer is disrupted (Farndale et al., 2004, J Thromb Haemost). Under physiological conditions, these proteins are sequestered within the vessel wall, but upon injury, they act as primary ligands for platelet receptors such as Glycoprotein VI (GPVI) and the GPIb-V-IX complex (Ruggeri, 2002, Nat Med). This interaction triggers platelet adhesion, activation, and the subsequent formation of a hemostatic plug or a pathological thrombus. In the context of cardiovascular disease, these exposed components are major drivers of arterial thrombosis, leading to clinical events like myocardial infarction and ischemic stroke. Therapeutic targeting of these ECM components, particularly through the use of soluble decoy receptors like Revacept (a GPVI-Fc fusion protein) or antibodies against vWF, aims to prevent thrombosis specifically at the site of injury (Ungerer et al., 2011, J Am Coll Cardiol). This localized approach is designed to maintain systemic hemostasis and reduce the bleeding risks associated with traditional antiplatelet therapies. Additionally, these components serve as molecular anchors for the targeted delivery of imaging agents and nanomedicines to damaged vasculature (Palo et al., 2012, Nanomedicine).

Other names

Subendothelial matrixVascular extracellular matrixExposed subendothelial proteinsVascular injury site

Competitive inhibition of platelet receptor binding to exposed subendothelial ligands (e.g., collagen, vWF) and site-specific recruitment of therapeutic or imaging agents to damaged vascular tissue (Nieswandt et al., 2011, Blood; Ungerer et al., 2011, J Am Coll Cardiol).